PersonFounderExecutive
Jeffrey Stafford
Jeffrey Stafford is the CEO and co-founder of 858 Therapeutics, a San Diego clinical-stage biotech developing small-molecule cancer drugs against novel targets in DNA-damage repair, innate immunity and RNA epigenetics. A chemist by training, he has spent three decades turning molecules into medicines: his discovery teams contributed to three FDA-approved drugs, and he previously led Jecure Therapeutics (acquired by Genentech in 2018) and co-founded Quanticel Pharmaceuticals (acquired by Celgene in 2015). 858's lead asset, the PARG inhibitor ETX-19477, won FDA Fast Track status and posted a 57% response rate in BRCA-mutated ovarian cancer at ASCO 2026.
jeffrey stafford858 therapeuticsceobiotech founderdrug discoveryoncology
